Dai Wang

US Patent:

8173362, May 8, 2012

Filed:

Apr 23, 2010

Appl. No.:

12/766611

Inventors:

Thomas Shenk - Princeton NJ, US
Dai Wang - Blue Bell PA, US

Assignee:

The Trustees of Princeton University - Princeton NJ

International Classification:

C12Q 1/70

US Classification:

435 5, 4242301, 424424, 4241921

Abstract:

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

US Patent:

20040241163, Dec 2, 2004

Filed:

Jan 27, 2004

Appl. No.:

10/473757

Inventors:

Thomas Shenk - Princeton NJ, US
Dai Wang - North Plainfield NJ, US

International Classification:

A61K039/395

US Classification:

424/145100

Abstract:

Novel pharmaceutical compositions and treatment methods are disclosed for chemokine-mediated inflammatory and immune-related pathological conditions. The pharmaceutical preparation comprises a chemokine binding activity from a supernatant of human cytomegalovirus (HCMV)-infected cells involving the secreted HCMV UL21.5 protein or functional fragment thereof and capable of binding the chemokine RANTES. Methods of treatment comprise administering a therapeutically effective amount of the UL21.5 activity-containing pharmaceutical preparation.

US Patent:

20080187545, Aug 7, 2008

Filed:

Jun 6, 2007

Appl. No.:

11/810578

Inventors:

Thomas Shenk - Princeton NJ, US
Dai Wang - Blue Bell PA, US

International Classification:

A61K 39/395
A61K 39/245
G01N 33/53
A61P 31/22
C07K 16/08

US Classification:

4241591, 4242301, 435 71, 5303894, 5303883

Abstract:

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

US Patent:

20100285059, Nov 11, 2010

Filed:

Oct 1, 2008

Appl. No.:

12/681504

Inventors:

Thomas Shenk - Princeton NJ, US
Dai Wang - Blue Bell PA, US

Assignee:

THE TRUSTEES OF PRINCETON UNIVERSITY - Princeton NJ

International Classification:

A61K 39/12
C12N 7/00

US Classification:

4242041, 4352351

Abstract:

Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed.

US Patent:

20120226023, Sep 6, 2012

Filed:

Mar 1, 2012

Appl. No.:

13/409987

Inventors:

Thomas Shenk - Princeton NJ, US
Dai Wang - Blue Bell PA, US

Assignee:

THE TRUSTEES OF PRINCETON UNIVERSITY - Princeton NJ

International Classification:

C07K 16/08
C07K 17/00
C12N 5/10

US Classification:

5303873, 5303894, 5303883, 435339, 5303911, 5303913, 5303917

Abstract:

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

US Patent:

20220280636, Sep 8, 2022

Filed:

Jul 14, 2020

Appl. No.:

17/626206

Inventors:

Arthur FRIDMAN - Rahway NJ, US
Jennifer Dawn GALLI - West Point PA, US
Dai WANG - West Point PA, US
Lan ZHANG - West Point PA, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/245
C12N 7/00

Abstract:

The disclosure relates to HSV glycoprotein E antigenic peptide constructs and HSV protein vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. The present invention directed to immunogenic polypeptides of use for a vaccine against Herpes Simplex Vims (HSV). The polypeptides are glycoprotein E peptides that are mutated to reduce their binding to antibody Fc domain.

US Patent:

20230114180, Apr 13, 2023

Filed:

Aug 30, 2022

Appl. No.:

17/823255

Inventors:

- Cambridge MA, US
Kapil Bahl - Medford MA, US
Amy Espeseth - Chalfont PA, US
Dai Wang - Blue Bell PA, US
Andrew J. Bett - Lansdale PA, US

Assignee:

ModernaTX, Inc. - Cambridge MA

International Classification:

A61K 39/12
A61P 31/14
A61K 9/00
A61K 9/51
C07K 16/10
C12N 7/00

Abstract:

The disclosure relates to respiratory syncytial vims (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

US Patent:

20200069792, Mar 5, 2020

Filed:

Apr 25, 2018

Appl. No.:

16/607412

Inventors:

Dai WANG - West Point PA, US
Lan ZHANG - West Point PA, US
- Rahway NY, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/245
C12N 7/00
A61P 31/22
C07K 14/005

Abstract:

The disclosure relates to HSV glycoprotein B and HSV glycoprotein C antigenic peptide constructs, HSV protein vaccines, and HSV DNA vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.